JNJ Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
25.3B
+5.2%
24.1B
-2.0%
24.6B
+2.4%
24.0B
+1.1%
23.7B
Cost of Revenue
8.1B
-0.7%
8.1B
+1.7%
8.0B
+9.1%
7.3B
-4.3%
7.6B
Gross Profit
17.3B
+8.2%
16.0B
-3.9%
16.6B
-0.6%
16.7B
+3.6%
16.1B
Operating Expenses
10.1B
+5.1%
9.6B
-13.8%
11.2B
+15.7%
9.7B
+2.0%
9.5B
R&D
3.7B
+2.5%
3.6B
-17.8%
4.3B
+18.0%
3.7B
+4.4%
3.5B
SG&A
6.4B
+6.6%
6.0B
-10.6%
6.8B
+14.0%
5.9B
+0.6%
5.9B
Operating Income
7.1B
+12.8%
6.3B
+16.6%
5.4B
-22.8%
7.0B
+5.8%
6.6B
EBITDA
9.1B
+9.2%
8.4B
+11.2%
7.5B
-15.2%
8.9B
+2.5%
8.7B
Net Income
5.5B
+5.7%
5.2B
+2.3%
5.1B
-0.7%
5.2B
-7.0%
5.5B
EPS (Basic)
$2.30
+6.0%
$2.17
+2.4%
$2.12
-0.9%
$2.14
-7.0%
$2.30
EPS (Diluted)
$2.27
+6.1%
$2.14
+2.4%
$2.09
-1.4%
$2.12
-7.4%
$2.29
Shares (Diluted)
2.4B
-0.2%
2.4B
-0.0%
2.4B
+0.7%
2.4B
+0.4%
2.4B
Johnson & Johnson (JNJ) โ€” Financials